Rani Therapeutics Holdings, Inc.
RANINASDAQHealthcare● Active
$0.84
+$0.00(+0.05%)
Market Cap$54868800
P/E Ratio—
52W High$3.87
52W Low$0.387
Rani Therapeutics Holdings, Inc. (RANI) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · RANI · as of 2026-06-09
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $1.63M | $1.03M | $0.00M | $0.00M | $2.72M |
| Cost of Revenue | $0.90M | $0.00M | $0.82M | $0.00M | $0.00M |
| Gross Profit | $0.73M | $1.03M | ($0.82M) | $0.00M | $2.72M |
| Gross Margin %(computed) | 44.89% | 100.00% | — | — | 100.00% |
| Operating Expenses | |||||
| R&D Expenses | $20.20M | $26.68M | $39.62M | $36.61M | $26.48M |
| G&A Expenses | $19.74M | $23.95M | $26.48M | $26.84M | $27.83M |
| Total Operating Expenses | $39.04M | $54.34M | $65.28M | $63.45M | $54.32M |
| Operating Income | ($38.31M) | ($53.31M) | ($66.10M) | ($63.45M) | ($51.60M) |
| Operating Margin %(computed) | — | — | — | — | — |
| Interest Income | $0.83M | $1.76M | $3.30M | $1.25M | $0.09M |
| Interest Expense | $2.89M | $5.03M | $5.08M | $1.07M | $0.47M |
| Income Before Tax | ($40.95M) | ($30.02M) | ($67.88M) | ($63.27M) | ($53.05M) |
| Income Tax Expense | $0.00M | $26.57M | $0.00M | $0.07M | $0.04M |
| Net Income | ($29.67M) | ($30.02M) | ($33.97M) | ($30.59M) | ($8.33M) |
| Net Margin %(computed) | — | — | — | — | -306.62% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-0.45 | $-1.05 | $-1.33 | $-1.28 | $-0.42 |
| Wtd Avg Shares | 66.14M | 28.48M | 25.50M | 23.82M | 19.53M |
| EBITDA | ($37.41M) | ($50.52M) | ($65.28M) | ($61.66M) | ($52.08M) |
| EBITDA Margin %(computed) | — | — | — | — | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-09 · USD · M
Explore more Rani Therapeutics Holdings, Inc. data
About Rani Therapeutics Holdings, Inc. (RANI) Income Statement
Rani Therapeutics Holdings, Inc. (RANI) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, RANI reported revenue of $0.00B, gross profit of $0.00B (gross margin 44.89%), and net income of ($0.03B) — a net profit margin of -1817.09%.
Frequently asked questions
RANI · 4 questionsRani Therapeutics Holdings, Inc. (RANI) reported revenue of $0.00B for 2025, up 58.9% year-over-year.
RANI revenueRANI salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09